Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Globus Medical ( (GMED) ) has issued an update.
On June 4, 2025, Globus Medical held its Annual Meeting of Stockholders, where several key proposals were approved. These included the amendment to the 2021 Equity Incentive Plan, the ratification of Deloitte & Touche LLP as the independent registered public accounting firm, and the approval of executive compensation. The stockholders also decided to hold an annual advisory vote on executive compensation.
The most recent analyst rating on (GMED) stock is a Buy with a $77.00 price target. To see the full list of analyst forecasts on Globus Medical stock, see the GMED Stock Forecast page.
Spark’s Take on GMED Stock
According to Spark, TipRanks’ AI Analyst, GMED is a Neutral.
Globus Medical’s stock score is bolstered by strong financial performance and strategic corporate actions like the Nevro acquisition and share buyback program. However, technical analysis indicates short-term weakness, and the high P/E ratio suggests a premium valuation, which may limit upside potential. The company’s ability to navigate operational challenges and execute its growth strategy will be key to future performance.
To see Spark’s full report on GMED stock, click here.
More about Globus Medical
Globus Medical, Inc. operates in the medical device industry, focusing on the design, development, and commercialization of healthcare products, particularly in the musculoskeletal sector.
Average Trading Volume: 1,549,014
Technical Sentiment Signal: Sell
Current Market Cap: $8.08B
For an in-depth examination of GMED stock, go to TipRanks’ Stock Analysis page.